查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086214

核酸檢測市場：2026-2032年全球市場預測（依產品類型、技術、檢體類型、目標分子、自動化程度、臨床用途、應用和最終用戶分類）

Nucleic Acid Testing Market by Product Type, Technology, Sample Type, Target Molecule, Degree Of Automation, Clinical Purpose, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，核酸檢測市場規模將達到 197.7 億美元，年複合成長率為 9.50%。

主要市場統計數據
基準年 2025 104.7億美元
預計年份：2026年 113.3億美元
預測年份 2032 197.7億美元
複合年成長率 (%) 9.50%

核酸檢測 (NAT) 是分子診斷領域的一個分支，用於檢測病原體、遺傳疾病、癌症生物標記、捐血樣本和其他臨床相關標靶中的 DNA 和 RNA。此領域包括聚合酵素鏈鎖反應(PCR)、逆轉錄 PCR、轉錄媒介增幅、恒溫環型核酸擴增、次世代定序和數位 PCR。其提案在於速度快、分析靈敏度高、特異性強，並且能夠在血清學檢測結果呈陽性之前檢測到感染。

感染疾病監測、血液篩檢、移植安全、癌症伴隨診斷、生殖醫學、抗菌素抗藥性監測和分散式檢查等領域持續為分子檢測提供結構性支撐。包括世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）、美國食品藥物管理局（FDA）、歐洲疾病預防控制中心（ECDC）、非洲疾病預防控制中心（African CDC）和國家參考實驗室在內的公共衛生組織，繼續將分子檢測定位為在人群層面發現集體爆發、制定治療策略和控制疾病的核心工具。

自然資源管理領域的變革性變化

核酸檢測格局正從集中式、高度複雜的檢查室轉向混合模式，這種模式結合了標準檢查室規模、即時檢測和便利的病患服務。新冠疫情加速了消費者對設備部署數量、檢體到結果工作流程、多參數呼吸道檢測組合、檢查室自動化、更快的結果交付速度以及供應鏈韌性的期望。

人工智慧的累積影響

人工智慧正開始影響核酸檢測的各個方面，從檢測設計、檢查室管理到結果解讀和流行病學分析。機器學習可以加速引子和探針的選擇，評估序列保守性，識別新出現的變異株，並在病原體變異時降低檢測失敗的風險。在定序流程中，人工智慧驅動的生物資訊學能夠改善變異株的識別、污染檢測以及臨床相關的分類。

主要區域洞察：亞太地區、北美地區、歐洲地區和新興地區

亞太地區是核酸檢測的優先發展區域，這得益於其龐大的患者群體、不斷擴展的醫院網路、結核病負擔、肝炎篩檢以及政府對國內診斷技術的投入。中國、印度、日本、韓國和澳洲是核酸檢測需求的主要來源，這體現在公共衛生計畫、腫瘤檢測、生殖健康、血液安全以及臨床和學術領域定序的日益普及等方面。

主要組織集團概況：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協的需求主要受登革熱、結核病、肝炎、愛滋病、流感和醫院感染監測的驅動，新加坡、泰國、馬來西亞、印尼、越南和菲律賓都在以不同的速度投資檢查室現代化。海灣合作理事會（GCC）的特點是醫療費用支出高、大量採用進口技術，以及國家層面的基因組學和精準醫療項目，這些都為自動化核酸擴增檢測（NAT）系統創造了機會。

主要NAT市場的特定國家洞察

美國透過獲得FDA批准和認證的檢測方法、CLIA認證的檢查室網路、醫院分子檢測以及對生物醫學研究的大力投入，引領著核酸擴增檢測（NAT）技術的創新。加拿大則專注於公共醫療採購、呼吸道病毒監測和腫瘤診斷，而墨西哥和巴西則透過公私合營的檢查室網路、血液安全措施和感染疾病控制項目來擴展分子檢測能力。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠滿足關鍵臨床需求、簡化可衡量的工作流程並符合不斷變化的監管要求的診斷方法和平台。最具吸引力的策略應結合檢驗的臨床性能、可擴展的生產能力、可靠的試劑供應、網路安全、與實驗室資訊系統的互通性以及明確的衛生經濟學證據。

調查方法

本執行摘要基於二手調查方法，採用公開權威資訊來源和交叉檢驗的行業指標。主要參考資料包括世界衛生組織疾病監測、美國疾病管制與預防中心實驗室指南、美國食品藥物管理局診斷政策、歐洲疾病預防控制中心公共衛生報告、體外診斷醫療器材法規（IVDR）監管資訊、非洲疾病預防控制中心優先事項、各國衛生機構、同行評審文獻以及既定的臨床實驗室醫學標準。

結論

核酸檢測已從一種專門的分子診斷工具發展成為現代醫學、公共衛生緊急準備、血液安全、腫瘤學和精準醫療的基礎要素。其持續重要性體現在早期發現、快速治療決策、抗生素抗藥性監測以及新發病原體的即時監測等。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：核酸檢測市場：依產品類型分類

  • 裝置
  • 試劑和試劑盒
  • 軟體服務

第8章：核酸檢測市場：依技術分類

  • 數位PCR
  • 等溫擴增
  • 微陣列
  • 次世代定序
  • 即時PCR

第9章：核酸檢測市場：依檢體類型分類

  • 血
  • 唾液
  • 拭子
  • 組織
  • 尿

第10章：核酸檢測市場：以標靶分子分類

  • DNA
  • RNA
  • DNA/RNA聯合檢測

第11章：核酸檢測市場：依自動化程度分類

  • 手動的
  • 半自動
  • 全自動

第12章：核酸檢測市場：依臨床應用分類

  • 篩檢
  • 確認檢查
  • 監測
  • 治療方案

第13章：核酸檢測市場：依應用領域分類

  • 臨床診斷
  • 藥物發現
  • 法醫學
  • 研究
  • 獸醫診斷

第14章：核酸檢測市場：依最終用戶分類

  • 學術研究機構
  • 診斷檢查室
  • 醫院和診所
  • 製藥和生物技術公司

第15章：核酸檢測市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第16章：核酸檢測市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 核酸檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第19章：公司簡介

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Grifols, SA
  • Hologic, Inc.
  • Illumina, Inc.
  • Meridian Bioscience, Inc.
  • Molbio Diagnostics Private Limited
  • Mylab Discovery Solutions Pvt. Ltd.
  • Natera, Inc.
  • Oxford Nanopore Technologies plc
  • Pacific Biosciences of California, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • QuidelOrtho Corporation
  • Revvity, Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Sonic Healthcare Limited
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
Product Code: MRR-036C5CF3B554

The Nucleic Acid Testing Market is projected to grow by USD 19.77 billion at a CAGR of 9.50% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 10.47 billion
Estimated Year [2026] USD 11.33 billion
Forecast Year [2032] USD 19.77 billion
CAGR (%) 9.50%

Nucleic acid testing, or NAT, is the molecular diagnostics category that detects DNA or RNA from pathogens, inherited conditions, oncology biomarkers, donor blood samples, and other clinically relevant targets. The field includes polymerase chain reaction, reverse transcription PCR, transcription-mediated amplification, loop-mediated isothermal amplification, next-generation sequencing, and digital PCR. Its value proposition is speed, analytical sensitivity, specificity, and the ability to detect infection before serology becomes positive.

Demand remains structurally supported by infectious disease surveillance, blood screening, transplant safety, oncology companion diagnostics, reproductive health, antimicrobial resistance monitoring, and decentralized testing. Public health agencies including WHO, CDC, FDA, ECDC, Africa CDC, and national reference laboratories continue to position molecular testing as a core tool for outbreak detection, treatment decisions, and population-level disease control.

Transformative Shifts in the NAT Landscape

The nucleic acid testing landscape is shifting from centralized, high-complexity laboratories toward a hybrid model that combines reference-lab scale with point-of-care and near-patient access. COVID-19 accelerated installed instrument bases, sample-to-answer workflows, multiplex respiratory panels, laboratory automation, and buyer expectations for faster turnaround times and supply-chain resilience.

A second shift is the move from single-analyte assays to syndromic, quantitative, and sequencing-enabled diagnostics. Hospitals and public health laboratories increasingly require tests that distinguish pathogens with overlapping symptoms, quantify viral load, and identify resistance markers. Regulatory scrutiny is also increasing, particularly for laboratory-developed tests and decentralized platforms, making analytical validation, clinical evidence, cybersecurity, and quality management central competitive differentiators.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence nucleic acid testing across assay design, laboratory operations, result interpretation, and epidemiologic intelligence. Machine learning can accelerate primer and probe selection, evaluate sequence conservation, flag emerging variants, and reduce the risk of assay dropout when pathogens mutate. In sequencing workflows, AI-supported bioinformatics improves variant calling, contamination detection, and clinically relevant classification.

The cumulative impact is operational as well as clinical. AI-enabled demand planning can help laboratories manage reagents and staffing, while automated signal interpretation can support digital PCR and high-throughput platforms. Industry leaders should treat AI as a validated decision-support layer, not a substitute for quality systems, clinical governance, and regulatory-grade evidence.

Key Regional Insights: Asia-Pacific, North America, Europe, and Emerging Regions

Asia-Pacific is a high-priority region for nucleic acid testing because of large patient populations, expanding hospital networks, tuberculosis burden, hepatitis screening, and government investment in domestic diagnostics. China, India, Japan, South Korea, and Australia anchor demand through public health programs, oncology testing, reproductive health, blood safety, and growing use of sequencing in clinical and academic settings.

North America remains the most mature commercialization environment, led by the United States and Canada, where FDA oversight, CLIA laboratories, broad hospital adoption, and reimbursement pathways shape innovation. Europe benefits from strong public health infrastructure, ECDC coordination, IVDR implementation, and established molecular diagnostics adoption across Germany, France, Italy, Spain, and the United Kingdom.

Latin America is expanding NAT access through infectious disease testing, blood safety, and private laboratory networks, with Brazil and Mexico serving as major demand centers. The Middle East is investing in precision medicine, transplant safety, and hospital modernization, especially in GCC markets. Africa is advancing molecular capacity through HIV viral load, tuberculosis, Ebola, mpox, and malaria surveillance, supported by Africa CDC, WHO programs, and donor-backed laboratory networks.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is supported by dengue, tuberculosis, hepatitis, HIV, influenza, and hospital-acquired infection surveillance, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines investing in laboratory modernization at different speeds. The GCC is characterized by high healthcare spending, imported technology adoption, and national genomics and precision medicine programs that create opportunities for automated NAT systems.

The European Union is defined by harmonized regulatory transition under the In Vitro Diagnostic Regulation, cross-border disease surveillance, and strong reference-laboratory capacity. BRICS economies combine scale with local manufacturing ambitions; China and India are particularly important for cost-optimized platforms and high-volume infectious disease testing. G7 markets influence global standards through regulatory science, reimbursement policy, and innovation funding, while NATO countries increasingly view molecular diagnostics as part of biosecurity, preparedness, and resilient medical supply chains.

Key Country Insights Across Major NAT Markets

The United States leads NAT innovation through FDA-cleared and authorized assays, CLIA-certified laboratory networks, hospital molecular testing, and strong biomedical funding. Canada emphasizes public healthcare procurement, respiratory virus surveillance, and oncology diagnostics, while Mexico and Brazil are expanding molecular capacity through public-private laboratory networks, blood safety, and infectious disease programs.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine advanced clinical laboratories with national health systems that prioritize evidence, cost-effectiveness, and regulatory compliance. Russia maintains domestic testing capacity for infectious disease and public health use. China is scaling local molecular platforms, oncology genomics, and infectious disease surveillance; India is expanding affordability-focused molecular access for tuberculosis, viral hepatitis, and reproductive health. Japan, South Korea, and Australia are mature, quality-driven markets with strong demand for automated, multiplex, and sequencing-based NAT solutions.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assays and platforms that address high-burden clinical needs, deliver measurable workflow efficiency, and comply with evolving regulatory expectations. The most defensible strategies combine validated clinical performance, scalable manufacturing, stable reagent supply, cybersecurity, interoperability with laboratory information systems, and clear health-economic evidence.

Organizations should also localize market access strategies. In mature markets, differentiation depends on automation, multiplexing, turnaround time, reimbursement support, and evidence generation. In emerging markets, success requires affordability, service uptime, training, sample logistics, and partnerships with public health agencies. AI, sequencing, and point-of-care NAT should be adopted with rigorous validation, transparent performance metrics, and post-market monitoring.

Research Methodology

This executive summary is built from a secondary research methodology using publicly available, authoritative sources and cross-validated industry indicators. Core reference points include WHO disease surveillance, CDC testing guidance, FDA diagnostics policy, ECDC public health reporting, IVDR regulatory information, Africa CDC priorities, national health agencies, peer-reviewed literature, and established laboratory medicine standards.

The analysis prioritizes verified trends over speculative estimates. Insights were synthesized across clinical use cases, technology platforms, regional healthcare infrastructure, regulatory frameworks, procurement behavior, and public health demand drivers. Market interpretation focuses on structural forces affecting nucleic acid testing adoption rather than unverified revenue projections.

Conclusion

Nucleic acid testing has moved from a specialized molecular tool to a foundational component of modern healthcare, public health preparedness, blood safety, oncology, and precision medicine. Its continued relevance is supported by the need for earlier detection, faster therapeutic decisions, antimicrobial resistance monitoring, and real-time surveillance of emerging pathogens.

The next phase of competition will be shaped by automation, multiplex panels, sequencing integration, AI-supported analytics, and decentralized access. Organizations that combine analytical accuracy with operational reliability, regulatory discipline, and market-specific affordability will be well positioned to advance in the global NAT ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Nucleic Acid Testing Market, by Product Type

  • 7.1. Instruments
  • 7.2. Reagents & Kits
  • 7.3. Software & Services

8. Nucleic Acid Testing Market, by Technology

  • 8.1. Digital PCR
  • 8.2. Isothermal Amplification
  • 8.3. Microarray
  • 8.4. Next Generation Sequencing
  • 8.5. Real Time PCR

9. Nucleic Acid Testing Market, by Sample Type

  • 9.1. Blood
  • 9.2. Saliva
  • 9.3. Swabs
  • 9.4. Tissue
  • 9.5. Urine

10. Nucleic Acid Testing Market, by Target Molecule

  • 10.1. DNA
  • 10.2. RNA
  • 10.3. Combined DNA/RNA

11. Nucleic Acid Testing Market, by Degree Of Automation

  • 11.1. Manual
  • 11.2. Semi-Automated
  • 11.3. Fully Automated

12. Nucleic Acid Testing Market, by Clinical Purpose

  • 12.1. Screening
  • 12.2. Confirmatory Testing
  • 12.3. Monitoring
  • 12.4. Treatment Selection

13. Nucleic Acid Testing Market, by Application

  • 13.1. Clinical Diagnostics
  • 13.2. Drug Discovery
  • 13.3. Forensics
  • 13.4. Research
  • 13.5. Veterinary Diagnostics

14. Nucleic Acid Testing Market, by End User

  • 14.1. Academic Research Institutes
  • 14.2. Diagnostic Laboratories
  • 14.3. Hospitals & Clinics
  • 14.4. Pharmaceutical & Biotechnology Companies

15. Nucleic Acid Testing Market, by Region

  • 15.1. Asia-Pacific
  • 15.2. North America
  • 15.3. Latin America
  • 15.4. Europe
  • 15.5. Middle East
  • 15.6. Africa

16. Nucleic Acid Testing Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Nucleic Acid Testing Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025

19. Company Profiles

  • 19.1. Abbott Laboratories
  • 19.2. Agilent Technologies, Inc.
  • 19.3. Becton, Dickinson and Company
  • 19.4. BGI Genomics Co., Ltd.
  • 19.5. Bio-Rad Laboratories, Inc.
  • 19.6. bioMerieux SA
  • 19.7. Danaher Corporation
  • 19.8. DiaSorin S.p.A.
  • 19.9. Exact Sciences Corporation
  • 19.10. F. Hoffmann-La Roche Ltd
  • 19.11. Grifols, S.A.
  • 19.12. Hologic, Inc.
  • 19.13. Illumina, Inc.
  • 19.14. Meridian Bioscience, Inc.
  • 19.15. Molbio Diagnostics Private Limited
  • 19.16. Mylab Discovery Solutions Pvt. Ltd.
  • 19.17. Natera, Inc.
  • 19.18. Oxford Nanopore Technologies plc
  • 19.19. Pacific Biosciences of California, Inc.
  • 19.20. Promega Corporation
  • 19.21. QIAGEN N.V.
  • 19.22. Quest Diagnostics Incorporated
  • 19.23. QuidelOrtho Corporation
  • 19.24. Revvity, Inc.
  • 19.25. Sansure Biotech Inc.
  • 19.26. Seegene Inc.
  • 19.27. Siemens Healthineers AG
  • 19.28. Sonic Healthcare Limited
  • 19.29. Sysmex Corporation
  • 19.30. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NUCLEIC ACID TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NUCLEIC ACID TESTING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NUCLEIC ACID TESTING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NUCLEIC ACID TESTING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NUCLEIC ACID TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL NUCLEIC ACID TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 29. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SOFTWARE & SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIGITAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIGITAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIGITAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MICROARRAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MICROARRAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MICROARRAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL REAL TIME PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL REAL TIME PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL REAL TIME PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SWABS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SWABS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SWABS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMBINED DNA/RNA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMBINED DNA/RNA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMBINED DNA/RNA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MANUAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MANUAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MANUAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEMI-AUTOMATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEMI-AUTOMATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEMI-AUTOMATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FULLY AUTOMATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FULLY AUTOMATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FULLY AUTOMATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CONFIRMATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CONFIRMATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CONFIRMATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MONITORING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MONITORING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MONITORING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TREATMENT SELECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TREATMENT SELECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TREATMENT SELECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CLINICAL DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG DISCOVERY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG DISCOVERY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG DISCOVERY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL FORENSICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL FORENSICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL FORENSICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL RESEARCH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL RESEARCH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ACADEMIC RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. GCC NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 174. GCC NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. GCC NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 178. GCC NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 179. GCC NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. G7 NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. G7 NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. G7 NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 205. G7 NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 206. G7 NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. NATO NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 211. NATO NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 214. NATO NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 215. NATO NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL NUCLEIC ACID TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. GERMANY NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 274. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 292. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 294. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. SPAIN NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 301. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 303. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 304. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. CHINA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 316. INDIA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 318. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 321. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 322. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 323. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 324. INDIA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. JAPAN NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 328. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 330. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 331. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 332. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. JAPAN NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 334. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 335. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 336. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 337. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 338. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 339. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 340. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 341. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 342. AUSTRALIA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 343. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 344. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 345. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 346. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY TARGET MOLECULE, 2018-2032 (USD MILLION)
  • TABLE 348. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY DEGREE OF AUTOMATION, 2018-2032 (USD MILLION)
  • TABLE 349. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY CLINICAL PURPOSE, 2018-2032 (USD MILLION)
  • TABLE 350. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 351. SOUTH KOREA NUCLEIC ACID TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)